Who Is Eligible for NexCAR19?

Two groups only. Relapsed or refractory B-cell non-Hodgkin lymphoma, and relapsed or refractory B-cell acute lymphoblastic leukaemia. In both, at least one prior line of therapy must have failed. The cancer must be CD19-positive on flow cytometry or immunohistochemistry. No other cancer is covered by the Indian approval.

NexCAR19 is a CD19-directed autologous CAR-T cell therapy developed by ImmunoACT, a spin-off of IIT Bombay, and developed in collaboration with Tata Memorial Centre. The Central Drugs Standard Control Organisation granted it market authorisation in October 2023, making it the first CAR-T cell therapy designed, manufactured and approved in India. Its international non-proprietary name is talicabtagene autoleucel; the earliest Indian announcements used the spelling actalycabtagene autoleucel, and both names refer to the same product.

The reason to start with the approved list rather than with how the therapy works is practical. Most families who reach this page have already been told that standard treatment has stopped working, and are trying to establish in an evening whether this is even a conversation worth having. That answer sits in two lines on a biopsy report: the exact subtype, and whether CD19 is expressed.

Fifteen years and above. That is the age stated in the Indian approval, for both the lymphoma and the leukaemia indication. There is no published upper age limit. Above 15, age by itself decides nothing — organ function and performance status carry the weight.

This single number causes more wasted travel than any other criterion in this cluster, in both directions. Parents of children under 15 are sent to Mumbai on the strength of a news headline about an Indian CAR-T therapy, only to be told at the counter that the approval does not reach their child. Families of a 70-year-old assume the opposite, that a person of that age is automatically too old, and never ask.

The age threshold is also one of the clearest differences between the Indian product and the imported ones, which carry their own age limits by indication. That comparison is set out in Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti, and it is worth reading before assuming that a no on one product is a no on all of them.

A cancer outside the approved list excludes permanently. So does CD19-negative disease. Active infection, active central nervous system disease, uncontrolled cardiac conditions, organ function below the stated thresholds, pregnancy and breastfeeding exclude a person at that moment. Several of those can be corrected, and the assessment is then repeated.

The criteria below are the ones the manufacturer publishes for treating clinicians. They exist for a specific reason. CAR-T is not a drug that is given and then adjusted; it is a single infusion of living cells that expands inside the body over the following two weeks and cannot be switched off. The organ thresholds are there because the person has to be well enough to sit out cytokine release syndrome and neurological toxicity if they happen.

Fixed exclusions and situational ones are not the same thing

This distinction is the whole value of reading the criteria early. A family told simply that the patient is “not eligible” often stops there, when in fact the barrier was a value on a blood report that changed within three weeks.

• Fixed for this product — a cancer outside the approved list, CD19-negative disease, and age under 15. None of these change with time or with a better report.
• Situational — active infection, deranged liver or kidney values, a low lymphocyte count, uncontrolled cardiac disease, active CNS involvement, or a performance status that has dropped during a difficult stretch. Each is reassessed rather than treated as final.

Prior stem cell transplant is a common source of confusion and belongs in neither list. The manufacturer states that patients who have had a prior transplant may still be eligible and are assessed case by case. Equally, a failed transplant is not a prerequisite — the requirement is one or more prior lines of therapy, which matters because a large share of people whose lymphoma relapses are never able to have a transplant at all.

The eligibility criteria mirror the population studied. NexCAR19 was assessed in an open-label phase 1/2 study across six tertiary cancer centres in India in 64 patients aged 15 and above, with results published in The Lancet Haematology in 2024 and summarised in the first-approval review indexed on PubMed. An overall response rate of 73% was reported in that study population. A response rate describes what happened to a group in a trial. It is not a prediction for any individual, and no test available today identifies in advance who will respond.

By a haematologist at a cell-therapy centre, working from the biopsy or flow-cytometry report, the record of prior lines, a current scan or marrow study, and a fresh set of organ-function tests. Nothing is decided from a phone description of the diagnosis, and nothing is decided by the family in advance.

What a family can do in advance is arrive with the right paper. Almost every avoidable delay in this pathway comes from a missing document rather than a missing criterion. The sequence usually runs like this.

1. Referral to a cell-therapy centre — the existing oncologist or haematologist refers, with a summary of the diagnosis and everything already given. Which hospitals qualify is covered in Where Is CAR-T Therapy Available in India?
2. Records review — the subtype, the number and type of prior lines, the response to each, and the dates. Discharge summaries and chemotherapy charts from every previous hospital are needed, not just the most recent one.
3. CD19 confirmation — flow cytometry or immunohistochemistry on the tumour. If an old biopsy is all that exists, a repeat may be requested.
4. Disease status — measurable disease at screening for lymphoma, and marrow blast assessment for leukaemia, with an evaluation of any extramedullary or CNS involvement.
5. Fitness workup — 2D echocardiogram, liver and kidney profile, blood counts with lymphocyte and CD3 counts, lung assessment, and the viral screen.
6. Leukapheresis feasibility — whether enough T cells can be collected, and whether the person is stable enough for a four-to-six-hour collection. Drug washout periods are planned at this point.
7. Slot scheduling and manufacturing — once accepted, a collection slot is allotted and manufacturing follows, described by the manufacturer as taking roughly three to four weeks. Bridging treatment may be given while waiting.

There is a second set of requirements that is not clinical and gets discovered far too late. The manufacturer’s patient guidance describes planning for roughly six to ten weeks around the treatment centre in total, and staying within about thirty minutes of the hospital with a caregiver for at least four weeks after the infusion. A working adult who cannot take that leave, or a family with no one able to stay, is in practical terms not able to proceed even when every clinical criterion is met.

Financial counselling belongs at the first appointment, not the last. Assistance routes and scheme applications take time to arrange, and starting them after acceptance rather than before is the commonest cause of a lost slot.

Yes, in both directions. Eligibility is assessed on the day, not once and for ever. Disease progression, a new infection, falling blood counts or a drop in performance status can close the window. Treating an infection, controlling CNS disease or giving bridging therapy can open it again.

This is where precise criteria stop being paperwork and start saving months. A family that knows exactly which line of the report is the problem can act on that line. A family told only that the answer is no tends to spend the next eight weeks travelling between hospitals for the same answer, while the one variable that could have been fixed drifts further out of range.

Clinical eligibility is one gate. A treating centre with an apheresis facility and intensive care backup is a second. Funding is a third. Families are often cleared on the first and stopped on the third, so all three are worth opening at the same time rather than in sequence.

On cost, the figures in circulation come from the manufacturer and from press coverage rather than from any hospital rate card. At launch, ImmunoACT’s leadership was widely quoted in the Indian pharmaceutical and general press putting the price at roughly ₹30–40 lakh, described in that coverage as about one-tenth of what approved CAR-T products cost in Western markets. The US National Cancer Institute’s February 2024 account of the therapy makes the same point about manufacturing in India at lower cost. Those are published third-party figures, indicative, as of August 2026, and they cover the product rather than the whole admission. Hospital stay, conditioning chemotherapy, apheresis, monitoring, and management of any complication are billed separately. What families actually end up paying, and the routes they use, are set out in the dedicated cost page in this section.

Government and trust hospitals change the arithmetic for some families, with their own waiting lists and subsidy rules — that is covered in Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists. Insurance and scheme coverage for cell therapy in India is still uneven and product-specific, and should be confirmed in writing before a slot is accepted.

To restate it plainly, because it decides where you should be reading: CION Cancer Clinics does not provide, administer or stock CAR-T or any other cell therapy, and no CION rate exists for this product. The immunotherapy given as day care at CION centres is checkpoint-inhibitor and antibody-based treatment, which is a different class of medicine. This page exists so that families reach the right kind of centre with the right documents, sooner.

If the eligibility criteria on this page appear to fit, the two practical questions that follow are where the therapy can be given and what it costs. Both have their own pages: Where Is CAR-T Therapy Available in India? lists what makes a centre able to deliver cell therapy, and Getting CAR-T at a Government Hospital: Subsidies and Waiting Lists covers the public and trust-hospital route.

If the criteria do not fit, the next question is usually whether another product might. Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti compares the approved indications, age limits and access routes across the products available here, and is the right page for anyone who has been told no on one product alone.

For the wider view across checkpoint inhibitors, biosimilars, cell therapies and the other medicine classes, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.